Idorsia (IDRSF) Set to Announce Quarterly Earnings on Thursday

Idorsia (OTCMKTS:IDRSF) will likely be announcing its results before the market opens on Thursday, October 29th. Analysts expect Idorsia to announce earnings of ($0.2273) per share and revenue of $63.70 million for the quarter.

Idorsia Price Performance

Shares of IDRSF opened at $5.38 on Tuesday. The stock has a 50-day moving average of $6.07 and a two-hundred day moving average of $5.66. Idorsia has a one year low of $3.50 and a one year high of $8.19.

Analyst Ratings Changes

IDRSF has been the topic of a number of recent research reports. HC Wainwright reiterated a “buy” rating on shares of Idorsia in a research report on Monday, September 14th. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Idorsia in a research note on Monday, August 3rd. One research analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, Idorsia presently has a consensus rating of “Moderate Buy”.

Idorsia Company Profile

Idorsia Ltd. is a Swiss biopharmaceutical company focused on discovering, developing and commercializing innovative medicines. The company conducts research in areas including central nervous system disorders, cardiovascular disease, immunology and orphan diseases, with the goal of addressing conditions that may have limited treatment options.

Idorsia was established in 2017 following the acquisition of Actelion by Johnson & Johnson. The company was formed to continue Actelion’s drug-discovery and development activities outside the acquired business.